Exploring QOL, hope, treatment motivition, coping en locus of control of patients considering early clinical cancer trial participation.
ID
Bron
Aandoening
Patients with solid tumors without standard treatment options considering participation in a phase I or phase II trial
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Outcome: <br>
The influence of ‘motivation for treatment, hope, coping, locus of control and quality of life’ on the decision whether or not to participate in a phase I or phase II cancer trial.<br>
Outcome Name: <br>
Participation or non participation in a phase I or II cancer trial, motivation for treatment, hope, coping, locus of control and quality of life’.<br>
The influence of ‘motivation for treatment, hope, coping, locus of control and quality of life’ will be measured using a questionair on different timepoint. The questionnaire contains 5 subquestionnaires: <br>
1. Validated 12 items motivation questionnaire by Prochaska en DiClemente;<br>
2. Validated 30 items coping questionnaire by Brandtstadter and Renner;<br>
3. Validated 19 item questionnaire by of the Rotter locus of controle scale;<br>
4. Validates 12 items questionnaire of the Herth Hope Index;<br>
5. Quality of life is measured with the EORTC QLQ-C30, 3.0.
Achtergrond van het onderzoek
Trial participation of cancer patients lacking standard treatment options is crucial for the development of new anti-cancer drugs. The main reason to participate is hope for remission or even cure. This study investigates the relationship of motivation for treatment, coping, locus of control, hope and quality of life in patients considering a phase I or II clinical cancer trial. Insight in these relationships could improve individualised patient information, within the legal settings, during the informed consent procedure and trial participation.
Doel van het onderzoek
Exploring QOL, hope, treatment motivition, coping en locus of control of patients considering early clinical cancer trial participation.
Onderzoeksopzet
1. Before deciding participation in a phase I or II trial;
2. After deciding to participate in a phase I or II trial;
3. When participating after the first evaluation of the effect of the treatment.
Onderzoeksproduct en/of interventie
N/A
Algemeen / deelnemers
Room G4-83<br>
Groene Hilledijk 301
A.J. Biessen, van der
Rotterdam 3075 EA
The Netherlands
+31 (0)10 7041132
a.vanderbiessen@erasmusmc.nl
Wetenschappers
Room G4-83<br>
Groene Hilledijk 301
A.J. Biessen, van der
Rotterdam 3075 EA
The Netherlands
+31 (0)10 7041132
a.vanderbiessen@erasmusmc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patients considering participation on a phase I or phase II trial for the first time.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Prior participation in phase I or II trial;
2. Age under 18 years.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL3203 |
| NTR-old | NTR3354 |
| Ander register | METC ErasmusMC : 11-106 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |